Stenting versus non-stenting treatment of intermediate stenosis culprit lesion in acute ST-segment elevation myocardial infarction： a multicenter random- ized clinical trial  

作　　者：Jing DAI Shu-Zheng LYU Yun-Dai CHEN Xian-Tao SONG Min ZHANG Wei-Min LI Yang ZHENG Shang-Yu WEN Shao-Ping NIE Yu-Jie ZENG Hai GAO Yi-Tong MA Shu-Yang ZHANG Li-Jun GUO Zheng ZHANG 

机构地区：[1]Department of Cardiology, Capital Medical University Affiliated Beijing Anzhen Hospital Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China [2]Department of Cardiology, Chinese PLA General Hospital, Beijing, China [3]Department of Cardiology, the First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China [4]Department of Cardiology, the First Bethune Hospital of Jilin University, Changchun, Jilin, China [5]Department of Cardiology, Daqing Oi[field General Hospital, Daqing, Heilongjiang, China [6]Department of Cardiology, the First Affiliated Hospital of Xinjiang Medical University, Urumchi, Xinjiang Uygur Autonomous Region, China [7]Department of Cardiology, Peking Union Medical College Hospital, Beijing, China [8]Department of Cardiology, Peking University Third Hospital, Beijing, China [9]Department of Cardiology, the First Hospital of Lanzhou University, Lanzhou, Gansu, China

出　　处：《Journal of Geriatric Cardiology》2017年第2期108-117,共10页老年心脏病学杂志（英文版）

摘　　要：Background The benefit/risk ratio of stenting in acute ST-segment elevation myocardial infarction （STEMI） patients with single vessel intermediate stenosis culprit lesions merits further study, therefore the subject of the present study. Methods and results It was a pro- spective, multicenter, randomized controlled trial. Between April 2012 and July 2015, 399 acute STEMI patients with single vessel disease and intermediate （40%-70%） stenosis of the culprit lesion before or after aspiration thrombectomy and/or intracoronary tirofiban （15 pg/kg） were enrolled and were randomly assigned （h 1） to stenting group （n = 201） and non-stenting group （n = 198）. In stenting group, patients received pharmacologic therapy plus standard percutaneous coronary intervention （PCI） with stent implantation. In non-stenting group, pa- tients received pharmacologic therapy and PCI （thrombectomy）, but without dilatation or stenting. Primary endpoint was 12-month rate of major adverse cardiac and eerebrovascular events （MACCE）, a composite of cardiac death, non-fatal myocardial infarction （M1）, repeat re- vascularization and stroke. Secondary endpoints were 12-month rates of all cause death, ischemia driven admission and bleeding complica- tion. Median follow-up time was 12.4 ~ 3.1 months. At 12 months, MACCE occurred in 8.0% of the patients in stenting group, as compared with 15.2% in the non-stenting group （adjusted HR： 0.42, 95% Ch 0.19-0.89, P = 0.02）. The stenting group had lower non-fatal MI rate than non-stenting group, （1.5% vs. 5.5%, P = 0.03）. The two groups shared similar cardiac death, repeat revascularization, stroke, all cause death, ischemia driven readmission and bleeding rates at 12 months. Conclusions Stent implantation had better efficacy and safety in reducing MACCE risks among acute STEMI patients with single vessel intermediate stenosis culprit lesions.

关 键 词：Acute myocardial infarction Anti-thrombotic therapy Clinical trial Primary percutaneous coronary intervention Stent ST-segment elevation myocardial infarction 

分 类 号：TB559[理学—物理] Q813.3[理学—声学]